Jazz Pharmaceuticals price target raised to $275 from $263 at BofA

BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $275 from $263 and keeps a Buy rating on the shares. Q4 results included modest top and bottom-line beats, while FY26 revenue guidance was about in-line with the firm’s forecast and 3% below consensus at the mid-point, notes the analyst, who argues that “solid” guidance should allow investors to own the stock for Ziihera gastroesophageal adenocarcinoma launch.